Biosimilars
Amgen Secures FDA Approval for Stelara Biosimilar, Awaits 2025 Launch Post-Settlement
The FDA has granted approval to Amgen for its biosimilar rendition of Johnson & Johnson’s renowned autoimmune medication, Stelara. However, ...
Roche, Biogen end patent dispute over Actemra biosimilar
Roche has swiftly resolved a patent infringement lawsuit it initiated against Biogen in July. The legal dispute centered around Biogen’s ...
Boehringer Ingelheim Adopts Dual-Pricing Strategy with Launch of Unbranded Humira Biosimilar
Boehringer Ingelheim, the company that recently introduced the first interchangeable biosimilar to AbbVie’s blockbuster drug Humira, is now embracing a ...
FDA Approves Biogenās Biosimilar, Challenging Rocheās Actemra Dominance in the Market
Biogen has achieved a remarkable milestone while contemplating the future of its biosimilars division. The company proudly announced that its ...
Biocon Biologicsā CEO reveals pricing strategy and device design for Hulio, its Humira biosimilar, in the US market
The competition in the biosimilar arena targeting AbbVie’s blockbuster drug Humira, also known as adalimumab, is heating up. However, for ...
Humira sales decline as biosimilars gain traction, but physicians remain wary of switching patients
In the race to capture a share of the $20 billion annual revenue generated by AbbVie’s blockbuster biologic, Humira biosimilars ...
Sandoz to market Samsung Bioepisā biosimilar of Stelara in US and Canada
Sandoz is expanding its biosimilar portfolio by signing a commercialization agreement with Samsung Bioepis for a biosimilar version of Johnson ...
Humira Biosimilars: Benefits, Availability, Price, Comparison and More
In this article, we will give you an overview of Humira biosimilars, including their benefits, availability, prices, and how they ...
Sandoz Enters US Immunology Market with Launch of High-Concentration Formulation Hyrimoz
Source – Novartis On July 1, 2023, Sandoz made an announcement regarding the availability of their biosimilar Hyrimoz (adalimumab-adaz) injection ...
Sandoz Aims for Success in Biosimilars, Forecasts $3 Billion in Sales from Pipeline Products in Next 5 Years
Sandoz, the generics and biosimilars division of Novartis, is set to become an independent company and is determined to reverse ...
